Clinical Trial: Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399678) titled 'Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D' on Jan. 15.

Brief Summary: A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Study Start Date: Dec. 29, 2025

Study Type: INTERVENTIONAL

Condition: Overweight or Obese Adults Overweight or Obese, Type 2 Diabetes

Intervention: DRUG: ALV-100

Participants will receive multiple ascending doses of ALV-100.

DRUG: Placebo

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Recruitment Status: RECRUITING

Sponsor: A...